Discerning Fact from Contrafaction: What One Needs to Know to Say No

Alfred H. Stammers, MSA, CCP

Objective: Identify the use, and misuse, of results from published studies based on the data gathered.

How many times have we had discussions with colleagues, or practitioners from an associated allied health field, expressing their desire to change how a perfusion technique or intervention is applied? This most often occurs following some event such as attendance at a meeting, speaking with a colleague, review of an article, or through the efforts of a company representative. Occasionally these discussions may emanate spontaneously or through some sentinel event that causes pause and reflection. Regardless, we are faced with the unpleasant task of justifying how our previously acceptable actions have served us, and our patients just fine, thank you. There exists, of course, those who are early adapters to new technology preferring to drive the bandwagon more so then be the last to climb onboard. Of course most of us would prefer to adopt change somewhere in the middle adopting a ‘wait and see’ philosophy. So how do we determine the validity of fact, or perhaps better stated, how do we interpret what is true science from that based on less rigorous methods. Why do some clinicians utilize techniques in medicine that others have trialed and abandoned? Why is it that discrepancies exist in outcomes when the same procedure when applied in one institution results in such different results when applied in another?

OPCAB

The controversy surrounding the use of the heart lung machine for surgical coronary revascularization has waged for almost a decade. In 2004 a paper was published that questioned the outcomes of graft patency in patients undergoing OPCAB surgery1.

Aprotinin

In January of this year a paper was published in the New England Journal of Medicine on aprotinin, a common pharmaceutical agent used in cardiovascular surgery2. This article reported that the use of this medication may result in "serious end-organ damage indicates that continued use is not prudent". Little catches the attention more quickly then a publication in a prestigious journal that contradicts established practice and goes against the preponderance of data to the contrary.

References

1 Khan NE, De Souza A, Mister R, Flather M, Clague J, Davies S, Collins P, Wang D, Sigwart U, Pepper J. A randomized comparison of off-pump and on-pump multivessel coronary-artery bypass surgery. N Engl J Med. 2004 Jan 1;350(1):21-8.

2 Mangano DT, Tudor IC, Dietzel C; Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation.The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006 Jan 26;354(4):353-65.

ABOUT US  |  CONTACT US                                                                                                     MAJOR SPONSORS:
Organization Logo Organization Logo  Organization Logo  
Last Modified: 16-May-2007
Copyright © 2008 by BestPracticePerfusion.org.